SMAD2/3 antibody | knockout validation | Cell Signaling 8685

This is a knockout-validated antibody summary, based on the publications "Efficient CRISPR/Cas9-Mediated Versatile, Predictable, and Donor-Free Gene Knockout in Human Pluripotent Stem Cells", as cited below [1], and "SMAD2/3 mediate oncogenic effects of TGF-β in the absence of SMAD4" for immunocytochemistry knockout validation (figure 1d) [2]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

SMAD2/3 antibody | knockout validation | Cell Signaling 8685 figure 1
Figure 1. Western blot of SMAD2/3 in WT and SMAD3 paired-KO H9 hESCs. From [1].
Antibody information

Rabbit monoclonal IgG

Company: Cell Signaling

Antibody: SMAD2/3

Catalog number: 8685

Summary: Rabbit monoclonal IgG against a synthetic peptide corresponding to residues surrounding His198 of human Smad2/3 protein. Reacts with human, mouse, rat, and monkey. Suitable for western blot, immunoprecipitation, immunofluorescence/immunocytochemistry, flow cytometry and ChIP.

Validation Method

Western blot

Sample

WT and SMAD3 paired-KO H9 hESCs. Cells were lysed in RIPA+ buffer.

Primary incubation

1:1,000 dilution.

Secondary incubation

Secondary antibodies were purchased from Jackson ImmunoResearch.

References
  1. Liu Z, Hui Y, Shi L, Chen Z, Xu X, Chi L, et al. Efficient CRISPR/Cas9-Mediated Versatile, Predictable, and Donor-Free Gene Knockout in Human Pluripotent Stem Cells. Stem Cell Reports. 2016;7:496-507 pubmed publisher
  2. Bertrand Chapel A, Caligaris C, Fenouil T, Savary C, Aires S, Martel S, et al. SMAD2/3 mediate oncogenic effects of TGF-β in the absence of SMAD4. Commun Biol. 2022;5:1068 pubmed publisher